Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $218,099.34 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total value of $218,099.34. Following the sale, the chief operating officer now owns 69,383 shares in the company, valued at $6,654,523.53. The trade was a 3.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $1.21 on Friday, hitting $90.14. The company’s stock had a trading volume of 1,266,828 shares, compared to its average volume of 690,804. The company has a market capitalization of $5.73 billion, a price-to-earnings ratio of -42.72 and a beta of 0.59. The firm has a fifty day moving average price of $92.45 and a 200-day moving average price of $97.23. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period in the previous year, the business earned ($2.20) earnings per share. The business’s revenue was up 126.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

Large investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC acquired a new position in shares of Blueprint Medicines during the second quarter valued at approximately $1,060,000. Federated Hermes Inc. lifted its holdings in Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock valued at $6,721,000 after purchasing an additional 13,579 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after buying an additional 82,693 shares in the last quarter. Nicholas Investment Partners LP purchased a new position in shares of Blueprint Medicines in the second quarter worth about $4,377,000. Finally, Entropy Technologies LP acquired a new position in Blueprint Medicines during the third quarter worth about $999,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BPMC. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.